Drugs News and Research

RSS

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine. The non-invasive and easy-to-use system provides automated results in one hour, enabling physicians to tailor treatments based on a patient's genotype faster than ever before.

11 Aug 2010

U.S. Senators introduce legislation to encourage R&D aimed at neglected pediatric diseases

"New bipartisan legislation was introduced in the U.S. Senate last week which seeks to encourage innovative [research and development] R&D by drugmakers aimed at treating rare and neglected pediatric diseases," PharmaTimes reports.

11 Aug 2010

Omnicell announces co-marketing partnership agreement for Sentinel RCM application

Omnicell, Inc., a leading provider of system solutions to acute healthcare facilities, today announced a partnership agreement to co-market Sentry Data Systems' Sentinel RCM™ application, which has a sophisticated 340B solution component. Sentry specializes in providing solutions to address a variety of financial challenges found within hospitals and pharmacies while Omnicell's WorkflowRx™ software offers a complete inventory management system for hospital pharmacies.

From Omnicell, Inc. 11 Aug 2010

China Nepstar Chain Drugstore second-quarter revenue increases 5.8% to RMB565 million

China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the quarter ended June 30, 2010.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.

11 Aug 2010

Scientists identify chemical system effective in cocaine-addiction cure

UT Southwestern Medical Center researchers have identified a chemical system in the brain that reacts differently in cocaine addicts, findings that could result in new treatment options for individuals addicted to the drug."We found that the amount of blood flow in areas of the brain known to be involved in the rewarding effects of cocaine and craving was different in cocaine addicts, compared with healthy subjects," said Dr. Bryon Adinoff, professor of psychiatry at UT Southwestern and lead author of a study that appeared in Neuropsychopharmacology. "Now we have a new target for pharmacologic intervention."

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

Education, changes in reimbursement practices can reduce inappropriate antibiotic usage: Study

Improved drug coverage under Medicare Part D has led to an increase in the use of antibiotics by seniors, particularly of brand-name and more expensive drugs, according to a University of Pittsburgh Graduate School of Public Health study. Published in the Aug. 23 issue of Archives of Internal Medicine and the first to explore spending on antibiotics under Medicare Part D, the study suggests recent changes in drug coverage improved the use of antibiotics for pneumonia, but could lead to unnecessary spending on expensive broad-spectrum antibiotics and the overuse of inappropriate antibiotics.

11 Aug 2010

Scientists develop new method to enable drug release inside cancer cells

Scientists from UCLA's California NanoSystems Institute and Korea's Yonsei University have developed an innovative method that enables nanomachines to release drugs inside living cancer cells when activated remotely by an oscillating magnetic field.The new system - the first to utilize a class of porous nanomaterials driven by a magnetic core - has the potential to improve both targeted drug-delivery and magnetic resonance imaging in the treatment of cancer and other diseases.

11 Aug 2010

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

11 Aug 2010

‘Decriminalize’ but not ‘Legalize’ drug abuse says Australian Sex party

Professor Paul Wilson, an Australian criminologist revealed that illegal drug use in Australia costs the nation $3.8 billion every year. Australian Sex Party however claims personal drug use should be decriminalized and drug abusers sent for rehabilitation instead of imprisonment.

10 Aug 2010

Telephone monitoring can save heart failure patients: Study

Chronic heart failure needs constant care and regular monitoring. Now research says remote monitoring, either over the phone or using wireless technology, helps people with heart failure live longer and stay out of hospital.

10 Aug 2010

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

The Canadian Agency for Drugs and Technologies in Health's (CADTH) Therapeutic Review Panel released last week their recommendations for Biologic Response Modifier Agents for Adults with Rheumatoid Arthritis (RA).

10 Aug 2010

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

China Sky One second-quarter 2010 total revenues up 26.7%

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the second quarter of 2010.

10 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Drugs News and Research

First complete sample-to-result, point-of-care DNA testing system for personalized medicine

U.S. Senators introduce legislation to encourage R&D aimed at neglected pediatric diseases

Omnicell announces co-marketing partnership agreement for Sentinel RCM application

China Nepstar Chain Drugstore second-quarter revenue increases 5.8% to RMB565 million

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Scientists identify chemical system effective in cocaine-addiction cure

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

Education, changes in reimbursement practices can reduce inappropriate antibiotic usage: Study

Scientists develop new method to enable drug release inside cancer cells

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

‘Decriminalize’ but not ‘Legalize’ drug abuse says Australian Sex party

Telephone monitoring can save heart failure patients: Study

CADTH Review Panel releases recommendations for Biologic Response Modifier Agents for Adults with RA

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

China Sky One second-quarter 2010 total revenues up 26.7%

China Pharma second-quarter revenue increases 22% to $16.6 million

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News